Cellartis human iPS cell-derived cardiomyocytes
An effective tool for in vitro evaluation of cardiotoxicity, drug discovery, and basic research
Cellartis cardiomyocytes display expected responses to the L-type Ca2+ channel blocker Nifedipine.
Human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) are emerging as popular tools for cardiac disease modeling because they eliminate the species-specific variations that can make results from animal models difficult to reproduce in humans, and unlike primary cells, are easier to obtain and have a longer lifespan. With more than 15 years of experience in stem cell generation and differentiation, Takara Bio has developed a dedicated portfolio of Cellartis stem cell products, including hiPS-CMs. Our spontaneously beating cardiomyocytes derived from hiPS cells make excellent in vitro tools for the study of human cardiomyocyte function and for cardiac safety pharmacology assays due to their:
- Expression of the major cardiac markers and ion channels
- Functional similarity to adult human cardiomyocytes
- Exhibition of physiologically relevant responses to compounds
Click here to download the brochure and learn how our cardiomyocytes can advance your research.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2022 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
